Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

6825 ARTÍCULOS , VIENDO DEL 6571 AL 6585

Dysregulation of the molecular clock by blood-borne factors in Alzheimer's disease patients

Zhao C, Li T, Hao S, Zhao L, Han Y, Cai Y.

J Neurol. 2025 Jan 15;272(2):121. doi: 10.1007/s00415-024-12824-0.

Proper Name Recall as an Early Indicator of Preclinical Alzheimer Disease Pathology

Mueller KD, Soldan A, Langhough R, Bruno D, Jauregi-Zinkunegi A, Basche K, Hale MR, He D, Moghekar A, Hermann B, Albert M, Pettigrew C.

Alzheimer Dis Assoc Disord. 2025 Oct-Dec 01;39(4):269-276. doi: 10.1097/WAD.0000000000000695. Epub 2025 Nov 10.

Association of neighborhood disadvantage with Alzheimer's disease pathology and the stability of blood-based biomarker performance

Myoraku A, Hausle I, Mila-Aloma M, Thropp P, Wang LA, Doraiswamy PM, Tosun D; Alzheimer’s Disease Neuroimaging Initiative*.

J Prev Alzheimers Dis. 2026 Feb;13(2):100445. doi: 10.1016/j.tjpad.2025.100445. Epub 2025 Nov 23.

The potential role of machine learning and deep learning in differential diagnosis of Alzheimer's disease and FTD using imaging biomarkers: A review

Mirabian S, Mohammadian F, Ganji Z, Zare H, Hasanpour Khalesi E.

Neuroradiol J. 2025 Oct;38(5):571-587. doi: 10.1177/19714009251313511. Epub 2025 Jan 9.

Validation status of cognitive digital assessments by the FDA BEST framework and context of use in preclinical AD studies: A systematic review

Porta-Mas C, Grau-Rivera O, Gispert JD, Blasco GS, Sánchez-Benavides G.

Alzheimers Dement. 2025 Dec;21(12):e70753. doi: 10.1002/alz.70753.

Amyloid Clearance and Transient CSF Aβ40 Reduction in a Case of ARIA-E/H Following Lecanemab Treatment

Naeshiro Y, Kitani-Morii F, Kasai T, Tanaka E, Kobayashi F, Ohara T.

Intern Med. 2026 Apr 1;65(7):1056-1060. doi: 10.2169/internalmedicine.6070-25. Epub 2025 Aug 21.

Clinimetrics: Towards a diagnostic neuropsychology grounded in Alzheimer's disease

Ilardi CR.

J Neuropsychol. 2026 Mar;20(1):246-255. doi: 10.1111/jnp.70008. Epub 2025 Aug 13.

Measurement Error and Methodologic Issues in Analyses of the Proportion of Variance Explained in Cognition

Nichols E, Aslanyan V, Adrien TV, Andrews RM, Fardo DW, Gavett BE, Paterson TSE, Turney IC, Young CB, Uanhoro JO, Gross AL, Initiative FTADN.

Neuropsychol Rev. 2025 Dec;35(4):731-744. doi: 10.1007/s11065-024-09655-1. Epub 2024 Nov 20.

[Advances in measurements and standardization of plasma phosphorylated tau217 as a biomarker for Alzheimer's disease]

Liu HY, Lin YL.

Zhonghua Yu Fang Yi Xue Za Zhi. 2025 Dec 6;59(12):2209-2215. doi: 10.3760/cma.j.cn112150-20250331-00265.

Electrochemical Technology for the Detection of Tau Proteins as a Biomarker of Alzheimer's Disease in Blood

Wang J, Lu X, He Y.

Biosensors (Basel). 2025 Feb 4;15(2):85. doi: 10.3390/bios15020085.

Early axonal degeneration linked to clinical decline in Alzheimer's disease progression revealed with diffusion MRI

Gong Z, Laporte JP, Guo AY, Bilgel M, Bae J, Fox NY, de Rouen A, Zhang N, Taranath A, de Cabo R, Egan JM, Ferrucci L, Bouhrara M; Alzheimer’s Disease Neuroimaging Initiative.

J Clin Invest. 2025 Nov 27;136(3):e196638. doi: 10.1172/JCI196638. eCollection 2026 Feb 2.

Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response?

Ricaurte-Fajardo A, Ivanidze J, Zhang D, Mahmud M, Yasen W, Ravdin L, Pahlajani S, Leon M, Nordvig AS, Chiang GC.

AJNR Am J Neuroradiol. 2025 Jul 1;46(7):1439-1445. doi: 10.3174/ajnr.A8654.

The Eye as a Window to Brain Health: Can Retinal Imaging and AI Modeling Predict Alzheimer's Disease?

Awodiya E.

Brain Behav. 2025 Oct;15(10):e70890. doi: 10.1002/brb3.70890.

Traumatic Brain Injury and Alzheimer's Disease Biomarkers: A Systematic Review of Findings from Amyloid and Tau Positron Emission Tomography

Dybing KM, Vetter CJ, Dempsey DA, Chaudhuri S, Saykin AJ, Risacher SL.

J Neurotrauma. 2025 Mar;42(5-6):333-348. doi: 10.1089/neu.2024.0055. Epub 2024 Dec 6.

Mass spectrometry-based methods for biofluid biomarkers for progressive diseases: amyloid peptides and dystrophins

Niwa M, Noda K, Kobayashi Y, Kageyama I, Kodama K.

Bioanalysis. 2025 May;17(10):671-680. doi: 10.1080/17576180.2025.2515011. Epub 2025 Jun 4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias